AGR2 and familial pancreatic carcinoma: Additionally, combining AGR2 antibodies with gemcitabine in mouse-transplanted human pancreatic cancers has demonstrated strong immunotherapeutic capabilities, exceeding gemcitabine treatment alone [19].